Amprenavir clinical trials
How each study uses amprenavir is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 15 Apr 1999 · AGENERASE · NDA 021007 (FDA, Drugs@FDA)
- European Union
- 20 Oct 2000 · Agenerase · EMEA/H/C/000264 (EMA; now withdrawn)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 1999 (5)
| Year | Studies |
|---|---|
| 1997 | 1 |
| 1999 | 5 |
| 2000 | 2 |
| 2001 | 3 |
| 2003 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 13 · Other 8
National Institute of Allergy and Infectious Diseases (NIAID) (7) · Glaxo Wellcome (7) · Boehringer Ingelheim (2) · Abbott (2) · ANRS, Emerging Infectious Diseases (1) · Hoffmann-La Roche (1) · Gilead Sciences (1)
Often tested with
Tested in the same studies.
Abacavir (11) · Ritonavir (7) · Efavirenz (6) · Saquinavir (3) · Lamivudine (3) · Adefovir dipivoxil (2) · Adefovir (2) · Indinavir (2)
Related medicines
As reviewed, each with the page that says it.
- One of Protease Inhibitors source
Studies
Open first, then newest update. How each study uses amprenavir is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 21
- Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-infected Patients in Virological Failure.CompletedPhase 2ANRS, Emerging Infectious DiseasesNCT00196625Written as Amprenavir (drug)
- Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected PatientsCompletedPhase 2Boehringer IngelheimNCT00056641Written as amprenavir
- A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken AmprenavirCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00001095Written as Amprenavir
- Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative VolunteersCompletedNot applicableNational Institute of Allergy and Infectious Diseases (NIAID)NCT00005762Written as Amprenavir
- Five-Drug Anti-HIV Treatment Followed by Treatment Interruption in Patients Who Have Recently Been Infected With HIVCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00000940Written as Amprenavir
- A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive PatientsCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00000912Written as Amprenavir
- Four-Drug Combination Therapy With Zidovudine, Lamivudine, 1592U89 (Abacavir), and 141W94 (Amprenavir) in HIV-Infected PatientsCompletedNot applicableNational Institute of Allergy and Infectious Diseases (NIAID)NCT00006617Written as Amprenavir
- Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine, Abacavir and Amprenavir in HIV-1 Infected Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Naive AdultsTerminatedPhase 1Boehringer IngelheimNCT02182765Written as Amprenavir
- Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAARTCompletedPhase 2AbbottNCT00038532Written as Amprenavir/ritonavir
- Continued Antiretroviral Therapy With Abacavir, Amprenavir and EfavirenzCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00001758Written as Amprenavir
- Once-Daily Drug Regimen for HIV-Infected PatientsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00001968Written as Amprenavir
- Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra as Their Second Protease InhibitorCompletedPhase 2/3AbbottNCT00038519Written as Amprenavir/ritonavir
- A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected AdultsCompletedPhase 2Hoffmann-La RocheNCT00002239Written as Amprenavir
- A Study of Amprenavir in Patients With Protease Inhibitor-Related ComplicationsCompletedNot applicableGlaxo WellcomeNCT00002417Written as Amprenavir
- Safety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavirenz Plus Amprenavir to HIV-Infected Patients Who Have Failed to Respond to Previous Protease Inhibitor TreatmentCompletedPhase 2Gilead SciencesNCT00002419Written as Amprenavir
- A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include AmprenavirCompletedPhase 2Glaxo WellcomeNCT00002423Written as Amprenavir
- A Study of the Effects of Amprenavir, a Protease Inhibitor, on Carbohydrate and Fat Metabolism in HIV-Infected PatientsCompletedPhase 3Glaxo WellcomeNCT00002245Written as Amprenavir
- Safety and Effectiveness of Giving Two Nucleoside Reverse Transcriptase Inhibitors Alone or in Combination With 141W94 to HIV-Infected Children Who Have Never Received Protease InhibitorsCompletedPhase 3Glaxo WellcomeNCT00002193Written as Amprenavir
- A Study of a Combination of Four Drugs in Patients With Recent HIV InfectionCompletedPhase 2Glaxo WellcomeNCT00002233Written as Amprenavir
- A Study of Amprenavir in HIV-Infected PatientsCompletedNot applicableGlaxo WellcomeNCT00002405Written as Amprenavir
Codes
What other systems call amprenavir · ClinicalTrials.gg INT003865
- MeSH (NLM) C095108amprenavirConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 5S0W860XNRAMPRENAVIRConfirmed FDA, NLM, Wikidata
- RxNorm 228656Confirmed FDA, Wikidata
- Wikidata Q422198amprenavirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C28824AmprenavirOne source FDA
- DrugBank DB00701One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C095108 | amprenavir | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 5S0W860XNR | AMPRENAVIR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 228656 | — | Confirmed FDA, Wikidata |
| Wikidata | Q422198 | amprenavir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C28824 | Amprenavir | One source FDA |
| DrugBank | DB00701 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.